Clinical Trial Details

Short Title
Official Title
Study to Determine Appropriate Dose of Medication for Patients with diagnosed with Recurring Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Who can apply: People diagnosed with recurring ovarian, primary peritoneal, or fallopian tube cancer.

Purpose: To determine the appropriate dose of an experimental drug, evaluate side effects when combined with other drugs, and test samples of tumor tissue (if available from a previous surgery or biopsy).

Drugs: ABT-888 (Veliparib), carboplatin and pegylated liposomal doxorubicin (PLD).

Number of participants: 10.

Start Date
July 17, 2012
End Date
July 17, 2022
Gender Preference
Age Group
18 - 99 years
Principal Investigator
David Bender, MD
Contact Info

Sharon Stockman, 319-356-2015

cancer ; Carboplatin ; De Geest ; endometrioid adenocarcinoma ; fallopian tube ; IRB#201206747 ; mixed epithelial carcinoma ; NCI Supplied Veliparib (ABT-888) ; ovarian clear cell cystadenocarcinoma ; Pegylated Liposomal Doxorubicin (PLD) ; Phase 1 ; Phase I ; Primary Peritoneal and Fallopian Tube Cancer ; recurrent epithelial cancer ; recurrent primary peritoneal cavity ; serous ; undifferentiated ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks